tldrdaily.news logo
Tag

Roivant Sciences

All articles tagged with #roivant sciences

politics-business2 years ago

Vivek Ramaswamy's Political Journey: From Presidential Campaign to Future Role with Trump

Vivek Ramaswamy's unsuccessful presidential campaign led to a $120 million increase in his wealth, bringing his estimated net worth to $960 million. Despite spending $17 million on his campaign, he profited from the sale of shares in Roivant Sciences and the growth of Strive Asset Management. Ramaswamy's future plans remain uncertain, with speculation about a return to the private sector or a potential role in a second Trump administration.

via Forbes|
#politics-business#presidential-campaign#roivant-sciences
finance2 years ago

October's Top Growth Stocks: No-Brainer Buys with Potential Soar

October historically tends to be a good month for stocks, and three growth stocks stand out as top buys for the final quarter of 2023: CRISPR Therapeutics, DraftKings, and Roivant Sciences. CRISPR Therapeutics is on the verge of making history with its CRISPR/Cas9 gene-edited sickle cell disease candidate, and its broad pipeline of candidates holds potential for treating various ailments. DraftKings, despite still losing money, has seen its stock soar due to its ability to grow revenue in the online gaming and sports-betting industry. Roivant Sciences, with its unique business strategy and two blockbuster immunology drugs, offers a compelling value proposition for investors.

via The Motley Fool|
#crispr-therapeutics#draftkings#finance
finance2 years ago

"Top Nasdaq Stocks Poised for Rapid Growth in the Coming Week"

BridgeBio Pharma and Roivant Sciences are two biotech companies with upcoming catalysts that could significantly boost their share prices. BridgeBio is set to announce top-line results from a phase 3 clinical study for its drug acoramidis, targeting a rare heart condition. Positive results could lead to a potential blockbuster drug and acquisition interest. Roivant Sciences may be acquired by Roche for its experimental inflammatory bowel disease drug, RVT-3101, in a rumored $7 billion deal. The potential windfall would greatly benefit Roivant's undervalued stock.

via The Motley Fool|
#acquisitions#biotech#bridgebio-pharma
business2 years ago

Pharmacy Firm's $7B Deal: Experimental Drug Sold to Roche

Roivant Sciences, a pharmaceutical company founded by Vivek Ramaswamy, is in talks to sell an experimental drug for the treatment of stomach diseases in a deal that could be valued at over $7 billion. The drug, RVT-3101, is currently in Phase 3 testing and has shown positive results. Roivant acquired the drug from Pfizer and formed a subsidiary called Telavant to fund its development. Roche, the fifth-largest pharmaceutical company globally, is reportedly ready to pay billions to secure the rights to the drug. If the deal goes through, it would be one of the biggest moves by Roche since its new CEO took over.

via New York Post |
#acquisition#business#drug-development
business2 years ago

Roivant's Stomach Drug Sale to Roche: A $7 Billion Deal in the Works

Biotech company Roivant Sciences, founded by Republican presidential candidate Vivek Ramaswamy, is in discussions to sell an experimental drug for a debilitating stomach disease to Roche Holding in a deal that could be worth over $7 billion. The drug is intended for the treatment of ulcerative colitis and Crohn's disease, which affects up to two million people in the United States.

via The Wall Street Journal|
#biotech#business#deal